p.89 抽出テキスト

725. Bunting KV, O’Connor K, Steeds RP, Kotecha D. Cardiac imaging to assess left ventricular systolic function in atrial fibrillation. Am J Cardiol 2021;139:40–9. https://doi. org/10.1016/j.amjcard.2020.10.012 726. Timperley J, Mitchell AR, Becher H. Contrast echocardiography for left ventricular opacification. Heart 2003;89:1394–7. https://doi.org/10.1136/heart.89.12.1394 727. Kotecha D, Mohamed M, Shantsila E, Popescu BA, Steeds RP. Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. Europace 2017; 19:1427–38. https://doi.org/10.1093/europace/eux027 728. Quintana RA, Dong T, Vajapey R, Reyaldeen R, Kwon DH, Harb S, et al. Preprocedural multimodality imaging in atrial fibrillation. Circ Cardiovasc Imaging 2022;15:e014386. https://doi.org/10.1161/CIRCIMAGING.122.014386 729. Laubrock K, von Loesch T, Steinmetz M, Lotz J, Frahm J, Uecker M, et al. Imaging of arrhythmia: real-time cardiac magnetic resonance imaging in atrial fibrillation. Eur J Radiol Open 2022;9:100404. https://doi.org/10.1016/j.ejro.2022.100404 730. Sciagrà R, Sotgia B, Boni N, Pupi A. Assessment of the influence of atrial fibrillation on gated SPECT perfusion data by comparison with simultaneously acquired nongated SPECT data. J Nucl Med 2008;49:1283–7. https://doi.org/10.2967/jnumed.108.051797 731. Clayton B, Roobottom C, Morgan-Hughes G. CT coronary angiography in atrial fibrillation: a comparison of radiation dose and diagnostic confidence with retrospective gating vs prospective gating with systolic acquisition. Br J Radiol 2015;88:20150533. https://doi.org/10.1259/bjr.20150533 732. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.e1–19. https://doi.org/10.1016/j.amjmed. 2005.10.057 733. Steinberg BA, Dorian P, Anstrom KJ, Hess R, Mark DB, Noseworthy PA, et al. Patient-reported outcomes in atrial fibrillation research: results of a Clinicaltrials.gov analysis. JACC Clin Electrophysiol 2019;5:599–605. https://doi.org/10.1016/j.jacep.2019. 03.008 734. Potpara TS, Mihajlovic M, Zec N, Marinkovic M, Kovacevic V, Simic J, et al. Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants, and implications for integrated holistic management of the arrhythmia. Europace 2020;22:1788–97. https://doi.org/10.1093/europace/euaa210 735. Moons P, Norekvål TM, Arbelo E, Borregaard B, Casadei B, Cosyns B, et al. Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management. Eur Heart J 2023;44:3405–22. https://doi. org/10.1093/eurheartj/ehad514 736. Allan KS, Aves T, Henry S, Banfield L, Victor JC, Dorian P, et al. Health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis. CJC Open 2020;2:286–95. https://doi.org/10.1016/j.cjco.2020.03.013 737. Vanderhout S, Fergusson DA, Cook JA, Taljaard M. Patient-reported outcomes and target effect sizes in pragmatic randomized trials in ClinicalTrials.gov: a cross-sectional analysis. PLoS Med 2022;19:e1003896. https://doi.org/10.1371/journal.pmed.1003896 738. Steinberg BA, Piccini JP, Sr. Tackling patient-reported outcomes in atrial fibrillation and heart failure: identifying disease-specific symptoms? Cardiol Clin 2019;37:139–46. https://doi.org/10.1016/j.ccl.2019.01.013 739. Härdén M, Nyström B, Bengtson A, Medin J, Frison L, Edvardsson N. Responsiveness of AF6, a new, short, validated, atrial fibrillation-specific questionnaire—symptomatic benefit of direct current cardioversion. J Interv Card Electrophysiol 2010;28:185–91. https://doi.org/10.1007/s10840-010-9487-3 740. Tailachidis P, Tsimtsiou Z, Galanis P, Theodorou M, Kouvelas D, Athanasakis K. The atrial fibrillation effect on QualiTy-of-Life (AFEQT) questionnaire: cultural adaptation and validation of the Greek version. Hippokratia 2016;20:264–7. 741. Moreira RS, Bassolli L, Coutinho E, Ferrer P, Bragança ÉO, Carvalho AC, et al. Reproducibility and reliability of the quality of life questionnaire in patients with atrial fibrillation. Arq Bras Cardiol 2016;106:171–81. https://doi.org/10.5935/abc.20160026 742. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramírez P, Badia X. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace 2010;12:364–70. https://doi.org/10.1093/europace/eup421 743. Braganca EO, Filho BL, Maria VH, Levy D, de Paola AA. Validating a new quality of life questionnaire for atrial fibrillation patients. Int J Cardiol 2010;143:391–8. https://doi. org/10.1016/j.ijcard.2009.03.087 744. International Consortium for Health Outcomes Measurement. Atrial fibrillation data collection reference guide Version 5.0.1. https://connect.ichom.org/wp-content/ uploads/2023/02/03-Atrial-Fibrillation-Reference-Guide-2023.5.0.1.pdf. 745. Dan GA, Dan AR, Ivanescu A, Buzea AC. Acute rate control in atrial fibrillation: an urgent need for the clinician. Eur Heart J Suppl 2022;24:D3–D10. https://doi.org/10.1093/ eurheartjsupp/suac022 746. Shima N, Miyamoto K, Kato S, Yoshida T, Uchino S; AFTER-ICU study group. Primary success of electrical cardioversion for new-onset atrial fibrillation and its association with clinical course in non-cardiac critically ill patients: sub-analysis of a multicenter observational study. J Intensive Care 2021;9:46. https://doi.org/10.1186/s40560-021- 00562-8 747. Betthauser KD, Gibson GA, Piche SL, Pope HE. Evaluation of amiodarone use for newonset atrial fibrillation in critically ill patients with septic shock. Hosp Pharm 2021;56: 116–23. https://doi.org/10.1177/0018578719868405 748. Drikite L, Bedford JP, O’Bryan L, Petrinic T, Rajappan K, Doidge J, et al. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. Crit Care 2021;25:257. https://doi.org/10.1186/ s13054-021-03684-5 749. Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, et al. Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. J Crit Care 2022;67:149–56. https://doi.org/10. 1016/j.jcrc.2021.11.005 750. Iwahashi N, Takahashi H, Abe T, Okada K, Akiyama E, Matsuzawa Y, et al. Urgent control of rapid atrial fibrillation by landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep 2019;1:422–30. https://doi.org/ 10.1253/circrep.CR-19-0076 751. Unger M, Morelli A, Singer M, Radermacher P, Rehberg S, Trimmel H, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials 2018;19:637. https://doi.org/10.1186/ s13063-018-3024-6 752. Gonzalez-Pacheco H, Marquez MF, Arias-Mendoza A, Alvarez-Sangabriel A, Eid-Lidt G, Gonzalez-Hermosillo A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol 2015;66:148–54. https://doi.org/10.1016/j.jjcc.2014. 11.001 753. Krijthe BP, Leening MJ, Heeringa J, Kors JA, Hofman A, Franco OH, et al. Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol 2013;168:1453–7. https://doi.org/10.1016/j.ijcard.2012.12.057 754. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014;174:107–14. https://doi.org/10.1001/jamainternmed.2013.11912 755. Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011;6:e24964. https://doi.org/10.1371/journal.pone.0024964 756. Coscia T, Nestelberger T, Boeddinghaus J, Lopez-Ayala P, Koechlin L, Miró Ò, et al. Characteristics and outcomes of type 2 myocardial infarction. JAMA Cardiol 2022;7: 427–34. https://doi.org/10.1001/jamacardio.2022.0043 757. Guimaraes PO, Zakroysky P, Goyal A, Lopes RD, Kaltenbach LA, Wang TY. Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction. Am J Cardiol 2019;123:12–8. https://doi.org/10.1016/j.amjcard.2018.09.031 758. Erez A, Goldenberg I, Sabbag A, Nof E, Zahger D, Atar S, et al. Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: real-world data from the Acute Coronary Syndrome Israeli Survey (ACSIS), 2000– 2013. Clin Cardiol 2017;40:275–80. https://doi.org/10.1002/clc.22654 759. Vrints C, Andreotti F, Koskinas K, Rossell X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 45:3415–537. https://doi.org/10.1093/eurheartj/ehae177 760. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 3720–826. https://doi.org/10.1093/eurheartj/ehad191 761. Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, et al. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis. Am Heart J 2022; 251:101–14. https://doi.org/10.1016/j.ahj.2022.05.019 762. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019;40:3757–67. https://doi.org/10.1093/eurheartj/ehz732 763. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107–15. https://doi.org/10.1016/S0140-6736(12) 62177-1 764. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380:1509–24. https://doi.org/10.1056/NEJMoa1817083 765. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–34. https://doi.org/10.1056/NEJMoa1611594 766. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377: 1513–24. https://doi.org/10.1056/NEJMoa1708454 767. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019;394:1335–43. https://doi.org/10. 1016/S0140-6736(19)31872-0 768. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026